Impella -Supported PCI in High-Risk Patients with Complex Coronary Artery Disease and Reduced Left Ventricular Function
Brief description of study
This study will examine whether using the Impella® device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and the health after a heart procedure compared to the current standard of care. The devices used in this study are already approved for use in patients like yourself by the Food and Drug Administration (FDA). The devices used in this Study include the Impella 2.5®, Impella CP® and Impella CP® with SmartAssist®.
Clinical Study Identifier: s21-00560
ClinicalTrials.gov Identifier: NCT04763200
Principal Investigator:
Louai Razzouk.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.